#dyslipidemia
LightNews LightNews
medicine.stitches.today
Oral LXR inverse agonist TLC-2716 cuts plasma triglycerides by up to 38.5% and shows promise for dyslipidemia management.

by Li X, Benegiamo G (...) Auwerx J et 13 al. in Nat Med #MedSky

👉 get more here

📖 read the article:
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial - Nature Medicine
The authors developed an LXR inverse agonist, TLC-2716, and show it is effective in reducing triglycerides and cholesterol in dysmetabolic preclinical models. Additionally, a phase 1 trial in healthy participants shows that TLC-2716 is well tolerated and reduces plasma triglycerides and postprandial remnant cholesterol, highlighting its potential for managing cardiovascular risk.
www.nature.com
January 25, 2026 at 6:46 PM
ajpcardio.bsky.social
New guidelines emphasize personalizing prevention for healthy cardiovascular aging by integrating geriatric cardiology principles into hypertension and dyslipidemia care. Tailored approaches may improve outcomes for older adults.
https://ow.ly/pfTB50Y1uh5

#GeriatricCardiology #CardioSky #MedSky
January 22, 2026 at 11:16 PM
llms.activitypub.awakari.com.ap.brid.gy
LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia Conditions : Hypertension; Diabetes; Dyslipidemia Interventions : Other: LLM-Enabled Clinician-P...

Origin | Interest | Match
ClinicalTrials.gov
clinicaltrials.gov
January 21, 2026 at 7:00 AM
scinews.bsky.social
First-in-human drug trial lowers high blood fats

"An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial"

www.nature.com/articles/s41...
January 18, 2026 at 7:58 PM
bionewscentral.com
An oral #compound was developed to lower #BloodTriglycerides by selectively inhibiting #LiverXReceptor in the #liver and #gut, offering a potential treatment for high triglyceride-related diseases.
#Triglycerides #Hypertriglyceridemia #Dyslipidemia
First-in-human drug trial lowers high blood triglycerides – BioNews Central
An oral compound was developed to lower triglycerides by selectively inhibiting Liver X Receptor in the liver and gut, offering a potential treatment for high triglyceride-related diseases. ...
sbee.link
January 17, 2026 at 2:51 AM
bigearthdata.ai
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial
->Nature | More from Lil Dr Glen EcoChat at BigEarthData.ai
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial
Biochemical binding assay Biochemical binding of TLC-2716 and TLC-6665 to LXRα or LXRβ was determined by time-resolved fluorescence resonance energy transfer-based biochemical assays evaluating the concentration-dependent displacement of a N-terminally biotinylated coactivator NCOA3 to recombinant glutathione S-transferase (GST)-tagged LXRα or...
www.nature.com
January 16, 2026 at 8:39 PM
ena11251134411.bsky.social
I was diagnosed with dyslipidemia

I’m working on improving my cholesterol levels

I’m focusing on my health this year

😭😭😭😭😭😭😭💪✨🔥
January 16, 2026 at 2:12 AM
docusalut.bsky.social
Nou article a #Docusalut: Determinants of Atherogenic Dyslipidemia and Lipid Ratios: Associations with Sociodemographic Profile, Lifestyle, and Social Isolation in Spanish Workers http://hdl.handle.net/20.500.13003/26126 @idisba.bsky.social  #PublicaSalutIB
January 15, 2026 at 5:30 PM
aging-us.bsky.social
🎧 Listen to our #pressrelease about the #research paper, titled "CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice."

soundcloud.com/aging-us/cd4...

#aging #audio #podcast #SoundCloud #PaperSpotlight #publishing #press
CD47 Antisense Therapy Improves Glucose Control and Lipid Balance in Aging Mice
BUFFALO, NY — January 15, 2026 — A new #research paper was #published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeosta
soundcloud.com
January 15, 2026 at 5:24 PM
aging-us.bsky.social
🎥 #AgingShort:
Abstract #video about this #research paper #published in Volume 17, Issue 12, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice.” @universityofky.bsky.social

🔗 www.aging-us.com/article/2063...

#aging #oa
January 15, 2026 at 5:04 PM
aging-us.bsky.social
🔆 #PaperSpotlight:
A new #research paper was #published on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice.” @universityofky.bsky.social

🔗 www.aging-us.com/article/2063...

#aging #quote #openaccess
January 15, 2026 at 3:34 PM
aging-us.bsky.social
🔆 #PaperSpotlight:
This #research paper was #published in Volume 17, Issue 12, titled "CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice."

#PressRelease ⬇️
aging-us.net/2026/01/15/c...

#aging #openaccess #publishing #press #meded
CD47 Antisense Therapy Improves Glucose Control and Lipid Balance in Aging Mice - Aging-US Authors
A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...
aging-us.net
January 15, 2026 at 3:21 PM
realbiomassspec.bsky.social
LC–MS‐Based Metabolomics Reveals Distinct Oxidative Stress Characteristics and Mechanisms in Endothelial Cells Stimulated by Sera From Dyslipidemia Patients With Phlegm‐Dampness Retention Syndrome and Spleen and ... #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
LC–MS‐Based Metabolomics Reveals Distinct Oxidative Stress Characteristics and Mechanisms in Endothelial Cells Stimulated by Sera From Dyslipidemia Patients With Phlegm‐Dampness Retention Syndrome and Spleen and Kidney Yang Deficiency Syndrome
This study aimed to explore the distinct metabolic profiles and potential mechanisms induced in endothelial cells stimulated by serum from patients with dyslipidemia presenting with Phlegm-Dampness ...
analyticalsciencejournals.onlinelibrary.wiley.com
January 9, 2026 at 7:44 PM
ucldiscovery.bsky.social
Open Access UCL Research: Association of Body Fatness With Hypertension, Dyslipidemia, and Myocardial Infarction in a Multinational Pooled Cohort discovery.ucl.ac.uk/id/eprint/10...
Association of Body Fatness With Hypertension, Dyslipidemia, and Myocardial Infarction in a Multinational Pooled Cohort - UCL Discovery
UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
discovery.ucl.ac.uk
January 8, 2026 at 4:10 PM
rarediseaseadvisor.bsky.social
Male sex, high body mass index (BMI), dyslipidemia, and smoking, among other factors, may cause increased risk for #IdiopathicPulmonaryFibrosis (#IPF) in individuals 75 or older. Published in @tarespirdis.bsky.social

Read here: https://bit.ly/4qDrxqF

#RareDisease #Pulmonology
Key Risk Factors Identified for IPF in Individuals Aged 75 or Older
An analysis of Korean insurance records showed that IPF risk factors may act additively or synergistically in older individuals.
bit.ly
January 6, 2026 at 5:47 PM
j9austin.bsky.social
🎧 Our podcast, "DNA Dialogues" is almost up to 12,000 downloads!

Here are our top episodes of the year:

Shifting Paradigms: #APOE in Dyslipidemia & Patient Voices in #Neurogenetics

DNA Day: Unexpected DTC Results & Gender Diverse Care

You can find them here:

dnadialogues.podbean.com

4/n
DNA Dialogues: Conversations in Genetic Counseling Research | Journal of Genetic Counseling (Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today’s Kira Dineen)
In DNA Dialogues we dive into the intricate world of genetic counseling research. Join us as we peel back the layers of groundbreaking articles from the Journal of Genetic Counseling, bringing you e...
dnadialogues.podbean.com
January 1, 2026 at 12:44 AM
medrxivpreprint.bsky.social
Increased Association Between Obstructive Sleep Apnea with Hypertension, Diabetes, Dyslipidemia, Chronic Renal Disease, and increasing weight with lower prevalence in cachexia https://www.medrxiv.org/content/10.64898/2025.12.29.25343183v1
December 31, 2025 at 4:55 AM
gracefuluniverse.bsky.social
#ecology #publichealth #agedcare #cardiology #hypertension #gerontology #health

Metals (Hg) -> high BP

PCBs (PCB156, PCB126) -> high systolic BP, FRS

Furans -> dyslipidemia, high LDL-C, triglycerides

Metals, PCBs, Dioxins, and Furans
and Cardiovascular Dysfunction
.
www.mdpi.com/2039-4713/15...
www.mdpi.com
December 28, 2025 at 7:41 AM
rozoruminations.bsky.social
🧵2/10
ACCESS targets 4 chronic conditions:

*Early Cardio-Kidney-Metabolic: Hypertension, dyslipidemia, obesity or overweight
*Cardio-Kidney-Metabolic: Diabetes, chronic kidney disease, atherosclerotic cardiovascular disease
*Chronic musculoskeletal pain
*Behavioral Health: Depression, Anxiety
December 22, 2025 at 12:04 AM
eurekamag.com
ICYMI: Efficacy and safety of statins in the treatment of diabetic dyslipidemia
Efficacy and safety of statins in the treatment of diabetic dyslipidemia
The Adult Treatment Panel III recommends 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins as first-line-lipid-altering therapy for all adult patients with diabetes mellitus. This is based on the well-characterized effic...
eurekamag.com
December 21, 2025 at 4:08 PM
drjwdietrich.bsky.social
#Hyperuricaemia is strongly associated with the metabolic syndrome (MetS). It is assumed that increased uric acid may be both cause and consequence of #MetS and its components (obesity, hypertension, dyslipidemia, and impaired glucose homeostasis, including type 2 diabetes)

1/2

🧪 🩺 #MedSky
December 21, 2025 at 10:02 AM
eurekamag.com
Efficacy and safety of statins in the treatment of diabetic dyslipidemia
Efficacy and safety of statins in the treatment of diabetic dyslipidemia
The Adult Treatment Panel III recommends 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins as first-line-lipid-altering therapy for all adult patients with diabetes mellitus. This is based on the well-characterized effic...
eurekamag.com
December 20, 2025 at 4:07 PM
eurekamag.com
ICYMI: Epidemiology of dyslipidemia in Tunisia, HSHS 3 study (Hammam Sousse Sahloul Heart Study)
Epidemiology of dyslipidemia in Tunisia, HSHS 3 study (Hammam Sousse Sahloul Heart Study)
Dyslipidemia is a major cause of morbidity and mortality worldwide because it increases the risk of cardiovascular diseases. To determine the prevalence of dyslipidemia and its components in the general population of Hammam Sousse (Tunisia)...
eurekamag.com
December 20, 2025 at 8:57 AM
eurekamag.com
Epidemiology of dyslipidemia in Tunisia, HSHS 3 study (Hammam Sousse Sahloul Heart Study)
Epidemiology of dyslipidemia in Tunisia, HSHS 3 study (Hammam Sousse Sahloul Heart Study)
Dyslipidemia is a major cause of morbidity and mortality worldwide because it increases the risk of cardiovascular diseases. To determine the prevalence of dyslipidemia and its components in the general population of Hammam Sousse (Tunisia)...
eurekamag.com
December 19, 2025 at 8:55 AM
halfwitty.bsky.social
Autistic people have significantly higher risk of diabetes, hypertension, dyslipidemia, stroke, and heart failure in a peer-reviewed study.
The authors underscore the importance of monitoring cardiometabolic health within the ASD population.
www.nature.com/articles/s44...
December 17, 2025 at 5:18 PM